Furthermore, increasing evidence suggests that TGF-β signaling inhibition would provide new therapeutic options for GBM tumors in which TGF-β acts to promote proliferation, survival, and EMT [68,69,70,71]. Here, TGFB1 is linked to glioblastoma.